During the malignant progression of CRC, TP53 mutations occur near the transition from benign to malignant lesion6, and indeed, the mutation incidence was shown to be about 80% when metastasis-associated CRCs were examined7. The gene discussed is TP53; the disease is colorectal carcinoma.